Paradigm Capital Management Inc. NY Invests $12 Million in Revvity Inc. $RVTY

Paradigm Capital Management Inc. NY acquired a new stake in Revvity Inc. (NYSE:RVTY) in the second quarter, Holdings Channel reports. The firm acquired 107,850 shares of the company’s stock, valued at approximately $11,999,000.

Other large investors have also recently added to or reduced their stakes in the company. EdgePoint Investment Group Inc. grew its stake in shares of Revvity by 3.1% in the first quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock worth $771,044,000 after acquiring an additional 265,204 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Revvity by 5.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company’s stock valued at $832,693,000 after acquiring an additional 434,570 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Revvity by 2.3% in the first quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock valued at $731,386,000 after acquiring an additional 186,956 shares in the last quarter. BlackRock Inc. purchased a new position in Revvity in the second quarter valued at $852,070,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Revvity by 11.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,917,953 shares of the company’s stock valued at $255,623,000 after purchasing an additional 305,837 shares during the period. 86.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on RVTY. Robert W. Baird set a $117.00 price target on Revvity in a report on Wednesday, May 6th. Wolfe Research began coverage on Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. TD Cowen restated a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Finally, Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 30th. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $108.36.

Revvity Stock Performance

Shares of RVTY stock opened at $123.08 on Tuesday. The company has a market cap of $13.73 billion, a P/E ratio of 58.61, a PEG ratio of 2.27 and a beta of 1.07. The firm has a fifty day moving average price of $111.90 and a 200 day moving average price of $100.48. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. Revvity Inc. has a 12 month low of $81.22 and a 12 month high of $124.97.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.Revvity’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period last year, the firm earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts predict that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be issued a $0.07 dividend. The ex-dividend date is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity’s dividend payout ratio is presently 13.33%.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.